170 related articles for article (PubMed ID: 36278778)
1. House dust mite allergen immunotherapy for monosensitized versus polysensitized patients with allergic rhinitis: A systematic review and meta-analysis.
Phinyo P; Krikeerati T; Wongyikul P; Lao-Araya M; Thongngarm T
Asian Pac J Allergy Immunol; 2022 Dec; 40(4):337-352. PubMed ID: 36278778
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Efficacy and Safety of Subcutaneous Immunotherapy in Monosensitized and Polysensitized Children With Allergic Rhinitis.
Yuan X; Xie S; Zhang H; Zhang J; Fan R; Jiang W; Xie Z
Otolaryngol Head Neck Surg; 2024 Mar; 170(3):919-927. PubMed ID: 38104318
[TBL] [Abstract][Full Text] [Related]
3. Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis.
Nelson HS; Bernstein DI; Biedermann T; Nolte H
Allergy Asthma Proc; 2024 Jan; 45(1):33-36. PubMed ID: 38151733
[No Abstract] [Full Text] [Related]
4. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
Huang HH; Xu C; Liu L; Chai RN
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
[No Abstract] [Full Text] [Related]
5. Long-Term Efficacy of Sublingual Mite Immunotherapy in Monosensitized and Polysensitized Children with Allergic Rhinitis: A 7-Year Prospective Study.
Cui L; Li J; Li Y; Xia Z
Int Arch Allergy Immunol; 2019; 180(2):144-149. PubMed ID: 31256165
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases.
Li P; Li Q; Huang Z; Chen W; Lu Y; Tian M
Int Forum Allergy Rhinol; 2014 Oct; 4(10):796-801. PubMed ID: 25145986
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sublingual dust mite drops in children with mono- or polysensitized allergic rhinitis.
Zhang YZ; Luo J; Wang ZH; Wang J
Am J Otolaryngol; 2019; 40(5):755-760. PubMed ID: 31327579
[TBL] [Abstract][Full Text] [Related]
8. Clinical Efficacy and Safety of Artesimia annua-Sublingual Immunotherapy in Seasonal Allergic Rhinitis Patients Based on Different Intervention Time.
Yang J; Shen Z; Liu L; Kang W; Shao Y; Zhang P; Quan F
Int Arch Allergy Immunol; 2022; 183(8):852-859. PubMed ID: 35413714
[TBL] [Abstract][Full Text] [Related]
9. Immunologic modification in mono- and poly-sensitized patients after sublingual immunotherapy.
Kim JY; Han DH; Won TB; Kim HJ; Lee CH; Rhee CS; Kim DY
Laryngoscope; 2019 May; 129(5):E170-E177. PubMed ID: 30548878
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Cohort Study of Sublingual Immunotherapy with Standardized Dermatophagoides farinae Drops for Allergic Rhinitis.
Ma X; Zhang Y; Gu X; Wu G; Liu J; Lu J; Yang H
Adv Ther; 2021 May; 38(5):2315-2322. PubMed ID: 33740216
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of sublingual immunotherapy with Dermatophagoides farina drops in monosensitized and polysensitized children with allergic rhinitis and asthma].
Xing QB; Chen S; Chen B; Li HF; Chen LL
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Feb; 31(3):204-208. PubMed ID: 29871223
[No Abstract] [Full Text] [Related]
12. [Effect of sublingual immunotherapy on patients with allergic rhinitis].
Yang J; Jiang H; Xiang YL; Wu Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Jan; 34(1):53-56. PubMed ID: 32086899
[No Abstract] [Full Text] [Related]
13. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy in one-year treatment with Artemisia annua-SLIT drops in monosensitized and polysensitized individuals.
Shen Z; Zhang P; Kang W; Chen X; Li H; Shao Y; Liu L; Quan F
Am J Otolaryngol; 2023; 44(6):104002. PubMed ID: 37478537
[TBL] [Abstract][Full Text] [Related]
15. The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis.
Zhao L; Zhang Y; Zhang S; Zhang L; Lan F
Expert Rev Clin Immunol; 2021 Sep; 17(9):969-975. PubMed ID: 34388949
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of sublingual immunotherapy with dermatophagoides farinae drops in monosensitized and polysensitized patients with allergic rhinitis].
Chen BY; Long ZM; Huang YJ; Zeng JM
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Jul; 48(7):549-54. PubMed ID: 24313202
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of house dust mite subcutaneous immunotherapy in polysensitized children with allergic asthma.
Zhang P; Jia Y; Jing Z; Huang J; Wu H; Sun X
Pulm Pharmacol Ther; 2023 Feb; 78():102187. PubMed ID: 36603742
[TBL] [Abstract][Full Text] [Related]
20. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis.
Wang ZX; Shi H
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):407-411. PubMed ID: 28585143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
